LT3456340T - Glp-1 receptoriaus antagonistas, skirtas įgimto hiperinsulinizmo gydymui - Google Patents

Glp-1 receptoriaus antagonistas, skirtas įgimto hiperinsulinizmo gydymui

Info

Publication number
LT3456340T
LT3456340T LTEP18201976.0T LT18201976T LT3456340T LT 3456340 T LT3456340 T LT 3456340T LT 18201976 T LT18201976 T LT 18201976T LT 3456340 T LT3456340 T LT 3456340T
Authority
LT
Lithuania
Prior art keywords
hyperinsulinism
glp
treatment
receptor antagonist
antagonist
Prior art date
Application number
LTEP18201976.0T
Other languages
English (en)
Inventor
Doris Stoffers
Diva D DE LEON
Charles Stanley
Original Assignee
The Trustees Of The University Of Pennsylvania
Children's Hospital Of Philadelphia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Trustees Of The University Of Pennsylvania, Children's Hospital Of Philadelphia filed Critical The Trustees Of The University Of Pennsylvania
Publication of LT3456340T publication Critical patent/LT3456340T/lt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
LTEP18201976.0T 2007-01-08 2008-01-08 Glp-1 receptoriaus antagonistas, skirtas įgimto hiperinsulinizmo gydymui LT3456340T (lt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US87903307P 2007-01-08 2007-01-08

Publications (1)

Publication Number Publication Date
LT3456340T true LT3456340T (lt) 2022-05-10

Family

ID=39609282

Family Applications (1)

Application Number Title Priority Date Filing Date
LTEP18201976.0T LT3456340T (lt) 2007-01-08 2008-01-08 Glp-1 receptoriaus antagonistas, skirtas įgimto hiperinsulinizmo gydymui

Country Status (14)

Country Link
US (7) US9821031B2 (lt)
EP (4) EP2818181B1 (lt)
CY (1) CY1125273T1 (lt)
DK (1) DK3456340T3 (lt)
ES (3) ES2710948T3 (lt)
FI (1) FI4049673T3 (lt)
HR (1) HRP20220346T3 (lt)
HU (1) HUE058307T2 (lt)
LT (1) LT3456340T (lt)
PL (1) PL3456340T3 (lt)
PT (1) PT3456340T (lt)
SI (1) SI3456340T1 (lt)
TR (1) TR201900959T4 (lt)
WO (1) WO2008085982A2 (lt)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2818181B1 (en) * 2007-01-08 2018-10-24 The Trustees Of The University Of Pennsylvania Compositions and medical uses thereof
WO2013120022A2 (en) * 2012-02-08 2013-08-15 Seneb Biosciences, Inc. Treatment of hypoglycemia
US10077319B2 (en) * 2014-02-21 2018-09-18 Medimmune, Llc Anti-PCSK9-GLP-1 fusions and methods for use
US11311519B2 (en) 2014-05-01 2022-04-26 Eiger Biopharmaceuticals, Inc. Treatment of hepatitis delta virus infection
WO2016141111A1 (en) * 2015-03-03 2016-09-09 Xoma (Us) Llc Treatment of post-prandial hyperinsulinemia and hypoglycemia after bariatric surgery
RS62368B1 (sr) 2015-05-22 2021-10-29 Univ Leland Stanford Junior Lečenje postbarijatrijske hipoglikemije eksendinom(9-39)
US10653753B2 (en) 2016-03-04 2020-05-19 Eiger Biopharmaceuticals, Inc. Treatment of hyperinsulinemic hypoglycemia with exendin-4 derivatives
BR112019010236A2 (pt) * 2016-11-21 2019-08-20 Eiger Biopharmaceuticals, Inc formulações tamponadas de exendina (9-39)
CN116606367A (zh) * 2022-05-31 2023-08-18 南京盛德瑞尔医药科技有限公司 长效Exendin-9-39及其在低血糖治疗中的应用和作为治疗低血糖的药物

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5424286A (en) * 1993-05-24 1995-06-13 Eng; John Exendin-3 and exendin-4 polypeptides, and pharmaceutical compositions comprising same
US20040092443A1 (en) * 1996-08-06 2004-05-13 Yeda Research And Development Co., Ltd Long-acting exendins and exendin agonists
ES2233089T3 (es) * 1998-12-10 2005-06-01 Agouron Pharmaceuticals, Inc. Antagonistas no peptidos del receptor de glp-1 y metodos de uso.
US6903074B1 (en) 1999-06-04 2005-06-07 Societe De Conseils De Recherches Et D'applications Scientifiques, S.A.S. Neuromedin b and somatostatin receptor agonists
SE0004462D0 (sv) * 2000-12-04 2000-12-04 Pharmacia Ab Novel method and use
WO2002066062A2 (en) * 2001-02-01 2002-08-29 Drucker Daniel J Enhancement of glp-2 activity
AU2002257132A1 (en) 2001-04-06 2002-10-21 The Trustees Of The University Of Pennsylvania Erbb interface peptidomimetics and methods of use thereof
CN1162446C (zh) * 2001-05-10 2004-08-18 上海华谊生物技术有限公司 促胰岛素分泌肽衍生物
US7378385B2 (en) 2002-08-08 2008-05-27 University Of Cincinnati Role for GLP-1 to mediate responses to disparate stressors
DE102004043153B4 (de) 2004-09-03 2013-11-21 Philipps-Universität Marburg Erfindung betreffend GLP-1 und Exendin
KR20090031368A (ko) 2006-05-26 2009-03-25 아밀린 파마슈티칼스, 인크. 울혈성 심부전 치료용 조성물 및 방법
EP2818181B1 (en) 2007-01-08 2018-10-24 The Trustees Of The University Of Pennsylvania Compositions and medical uses thereof
DK2310042T3 (da) 2008-07-08 2013-03-04 Novartis Ag Anvendelse af pasireotid til behandling af endogen hyperinsulinæmisk hypoglykæmi
AU2010258898B8 (en) 2009-06-08 2015-02-05 Amunix Operating Inc. Glucose-regulating polypeptides and methods of making and using same
US9932381B2 (en) 2014-06-18 2018-04-03 Sanofi Exendin-4 derivatives as selective glucagon receptor agonists
RS62368B1 (sr) 2015-05-22 2021-10-29 Univ Leland Stanford Junior Lečenje postbarijatrijske hipoglikemije eksendinom(9-39)
BR112019010236A2 (pt) 2016-11-21 2019-08-20 Eiger Biopharmaceuticals, Inc formulações tamponadas de exendina (9-39)

Also Published As

Publication number Publication date
FI4049673T3 (fi) 2026-03-13
ES2908838T3 (es) 2022-05-04
EP3456340B1 (en) 2022-02-16
US9616108B2 (en) 2017-04-11
HUE058307T2 (hu) 2022-07-28
US10188702B2 (en) 2019-01-29
US20080269130A1 (en) 2008-10-30
ES2710948T3 (es) 2019-04-29
EP3456340A1 (en) 2019-03-20
TR201900959T4 (en) 2019-02-21
EP2120994A4 (en) 2011-09-28
SI3456340T1 (sl) 2022-08-31
DK3456340T3 (da) 2022-03-21
US9821031B2 (en) 2017-11-21
EP4049673B1 (en) 2026-01-28
EP2120994A2 (en) 2009-11-25
EP2120994B1 (en) 2014-06-11
EP2818181A1 (en) 2014-12-31
WO2008085982A3 (en) 2008-11-20
US20180050095A1 (en) 2018-02-22
US20210252110A1 (en) 2021-08-19
EP4049673A1 (en) 2022-08-31
US20100190700A1 (en) 2010-07-29
US20250312420A1 (en) 2025-10-09
US10987407B2 (en) 2021-04-27
PT3456340T (pt) 2022-05-25
US20240082361A1 (en) 2024-03-14
EP2818181B1 (en) 2018-10-24
CY1125273T1 (el) 2023-06-09
US20190336584A1 (en) 2019-11-07
HRP20220346T3 (hr) 2022-09-02
ES2499390T3 (es) 2014-09-29
WO2008085982A2 (en) 2008-07-17
PL3456340T3 (pl) 2022-08-22

Similar Documents

Publication Publication Date Title
CY2020036I1 (el) Δοσολογικο σχημα για εναν αγωνιστη του υποδοχεα s1p
NO2025029I1 (no) Entrectinib or isomers, tautomers, or pharmaceutically acceptable salts therof - forlenget
LTC2379069I2 (lt) S1p receptoriaus agonisto dozavimas
BRPI0912362A2 (pt) antagonista do receptor nmda para o tratamento de transtornos neuropsiquiátricos
LTC2459208I2 (lt) Terapiniai agentai, skirti prieskydinės liaukos hormono lygio sumažinimui
LT3456340T (lt) Glp-1 receptoriaus antagonistas, skirtas įgimto hiperinsulinizmo gydymui
EP2300037A4 (en) COAGONISTS OF GLUCAGON / GLP-1 RECEPTOR
EP2150115A4 (en) CYCLOPROPYLPYRROLIDINOREXIN Receptor Antagonists
ATE509022T1 (de) Nikotin-acetylcholin-rezeptorsubtyp-selektive diazabicycloalkanamide
DK2094709T3 (da) Thiazol-pyrazolopyrimidiner som CRF1-receptorantagonister
DK2252581T3 (da) Kappa-selektiv opioidreceptorantagonist
BRPI0814768A2 (pt) Uso terapêutico de anticorpos de receptores anti-tweak
IL196470A (en) Antagonist antibody for the treatment of cancer
BRPI0910118A2 (pt) antagonistas de receptores do glucagon
BRPI0907364A2 (pt) Antagonistas aminoalquilbifenil n,n-disubstituídos de receptores d2 de prostaglandina
DK2081951T3 (da) Progesteron-receptorantagonister
BRPI0717937A2 (pt) Compostos de pirazona como antagonistas do receptor mineralocorticóide
DK2501703T3 (da) Spiropiperidinforbindelser som orl-1-receptorantagonister
DK1729753T3 (da) Anvendelse af en NMDA-receptor-antagonist til behandling af tinnitus induceret ved kokleær excitotoksicitet
BRPI0912988A2 (pt) compostos bicíclicos tendo atividade no receptor cxcr4.
DK2041093T3 (da) Til behandling af GPR38-receptor medierede sygdomme anvendelige piperazinylderivativer
DK2401270T3 (da) Pyrazolderivater anvendt som CCR4-receptorantagonister.
DK2367542T3 (da) Orale doseringsformer af bendamustin
DK2398780T3 (da) Cyclopropylamidderivater, som er målrettet mod histamin H3-receptoren
HRP20160950T1 (hr) Polimorfi antagonista mglur5 receptora